Vanguard Group’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-69,733
| Closed | -$350K | – | 4388 |
|
|
2024
Q3 | $350K | Hold |
69,733
| – | – | ﹤0.01% | 4049 |
|
|
2024
Q2 | $460K | Buy |
69,733
+12,130
| +21% | +$82.5K | ﹤0.01% | 4031 |
|
|
2024
Q1 | $634K | Buy |
57,603
+6,809
| +13% | +$73.7K | ﹤0.01% | 3956 |
|
|
2023
Q4 | $686K | Buy |
50,794
+22,919
| +82% | +$372K | ﹤0.01% | 3940 |
|
|
2023
Q3 | $605K | Buy |
27,875
+3,431
| +14% | +$110K | ﹤0.01% | 4000 |
|
|
2023
Q2 | $941K | Buy |
24,444
+382
| +2% | +$13.5K | ﹤0.01% | 3922 |
|
|
2023
Q1 | $667K | Buy |
24,062
+461
| +2% | +$15.6K | ﹤0.01% | 4037 |
|
|
2022
Q4 | $777K | Buy |
23,601
+10
| +0% | +$729 | ﹤0.01% | 3988 |
|
|
2022
Q3 | $2.86M | Buy |
23,591
+787
| +3% | +$142K | ﹤0.01% | 3603 |
|
|
2022
Q2 | $3.99M | Buy |
22,804
+2,180
| +11% | +$460K | ﹤0.01% | 3496 |
|
|
2022
Q1 | $5.98M | Buy |
20,624
+1,470
| +8% | +$558K | ﹤0.01% | 3444 |
|
|
2021
Q4 | $10M | Buy |
19,154
+15,450
| +417% | +$11.1M | ﹤0.01% | 3204 |
|
|
2021
Q3 | $1.41M | Buy |
3,704
+64
| +2% | +$27.4K | ﹤0.01% | 4165 |
|
|
2021
Q2 | $3.25M | Buy |
3,640
+601
| +20% | +$460K | ﹤0.01% | 3805 |
|
|
2021
Q1 | $3.62M | Buy |
3,039
+1,159
| +62% | +$1.6M | ﹤0.01% | 3687 |
|
|
2020
Q4 | $2.5M | Buy |
1,880
+1,572
| +510% | +$2.31M | ﹤0.01% | 3608 |
|
|
2020
Q3 | $694K | Buy |
308
+28
| +10% | +$63.3K | ﹤0.01% | 3747 |
|
|
2020
Q2 | $630K | Buy |
+280
| New | +$762K | ﹤0.01% | 3714 |
|
Vanguard Group's BIOR Position: Q4 2024 in Review
Vanguard Group sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 69,733 shares — an estimated $350K sold.
Vanguard Group first reported a position in BIOR in Q2 2020 and held it in 18 quarters. The position peaked at $10M in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- Vanguard Group reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Vanguard Group sold 69,733 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $350K.
- Vanguard Group first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- Vanguard Group's Biora Therapeutics, Inc. Common Stock position peaked at $10M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.